Rajesh Rohatgi, MD
Nuclear Cardiology · Garden City, NYNPI 1932118528
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 72 payments — averaging $61.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$634
- Harmony Biosciences LLC$374
- Mallinckrodt Enterprises LLC$339
- Mallinckrodt Hospital Products Inc.$334
- GSK$333
- Sanofi-aventis U.S. LLC$250
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,418100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $634 |
| Harmony Biosciences LLC | 11 | $374 |
| Mallinckrodt Enterprises LLC | 3 | $339 |
| Mallinckrodt Hospital Products Inc. | 3 | $334 |
| GSK | 5 | $333 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Mylan Specialty L.p. | 2 | $245 |
| Regeneron Healthcare Solutions, Inc. | 2 | $162 |
| Merck | 1 | $125 |
| Johnson & Johnson | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Exelixis Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Dexcom, Inc. | 1 | $109 |
| Gilead | 2 | $100 |
| Novo Nordisk | 4 | $85 |
| Exact Sciences | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Amgen | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Pfizer | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Grifols USA, LLC | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,418 in reported general payments places this provider in the 65th percentile of 21 nuclear cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 452 | $209,925 |
| JanuviaSitagliptin Phosphate | 164 | $86,777 |
| JardianceEmpagliflozin | 82 | $62,508 |
| OzempicSemaglutide | 39 | $38,320 |
| XareltoRivaroxaban | 66 | $31,212 |
| TradjentaLinagliptin | 47 | $26,209 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,869 |
| EntrestoSacubitril/Valsartan | 30 | $21,357 |
| SantylCollagenase Clostridium Hist. | 53 | $20,851 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $16,789 |
| Atorvastatin Calcium | 1,131 | $14,765 |
| Incruse ElliptaUmeclidinium Bromide | 36 | $13,316 |
| MyrbetriqMirabegron | 26 | $13,288 |
| TrulicityDulaglutide | 13 | $12,468 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $11,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $32 | $217,471476 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $125 | $100,686152 claims |
| MerckJanuvia | $125 | $86,777164 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $333 | $52,974107 claims |
| Novo NordiskOzempic | $85 | $38,32039 claims |
| Johnson & JohnsonXarelto | $125 | $31,21266 claims |
| NovartisEntresto | $18 | $21,35730 claims |
| Lilly USA, LLCTrulicity | $125 | $12,46813 claims |
| AstraZenecaBrilinta, Symbicort | $634 | $12,41239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 nuclear cardiology providers in New York.
Other nuclear cardiology in Garden City
- Klaus RentropNew York$5.6M
- Diwakar JainHawthorne$105K
- John AsheldWest Islip$24K
- Brian RiegelWilliamsville$23K
- Wilbur AsheldWest Islip$11K
- Jonathan WeinsaftNew York$10K
- Ossama SamuelBrooklyn$7K
- Harout YacoubNew York$2K
- Nicholas PapapietroBrooklyn$2K
- Ahmad Nawid LatifiRochester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.